Industry News
Reeves a super ambassador for research, says Trounson
'Superman' actor Christopher Reeves, who died yesterday in the US from complications of an infection, was a great ambassador for stem cell research and raised the profile of research around the world, Monash University's Alan Trounson said today. [ + ]
How Biota could benefit from flu vaccine debacle
After running out of influenza vaccines during last winter's major epidemic, the US confronts the prospect of an even more severe shortfall in the coming season. [ + ]
Peplin slumps as Allergan collaboration ends
Peplin's share price has dropped 30 per cent today (Monday) on heavy trading after the company announced late on Friday that its collaboration with Allergan was to be discontinued, and all rights for the development and commercialisation of the company's topical skin cancer drug, PEP005 Topical, as well as data and IP generated during the collaboration, are to be returned to the Brisbane-based company. [ + ]
In brief: Sirtex, GTG, LCT, Bone
Independent clinical studies performed in the US, Europe and Australia have verified the efficacy of Sirtex Medical's (ASX:SRX) SIR-Spheres liver cancer treatment. [ + ]
Anti-GM movement knew of 'secret' trials
Claims by anti-GM activists that the Victorian government and Bayer CropScience are putting farmers' livelihoods at risk, by keeping secret the locations of genetically modified canola trials, have been scotched with the revelation that they have known the location of at least one participating farm for more than a year. [ + ]
Poll claims medical research is big issue
Yet another public opinion poll has found that Australians want a substantial increase in funding for medical research. [ + ]
Astrophysicists to create biggest telescope
Astrophysicists from Cambridge and New Mexico are to join in creating the world’s most ambitious optical astronomical telescope array based on a concept pioneered in the UK.
[ + ]Medal win
Mathematician Dr Bob Anderssen has been awarded the George Szekeres Medal for his outstanding research achievements.
[ + ]AustCancer attracts $2m investment
US biotech company Bioaccelerate will invest AUD$1.88 million into Australian Cancer Technologies (AustCancer, ASX:ACU) through a private share placement of 4,893,301 ACU shares at $0.384 per share. [ + ]
Q-Vis rises from the ashes -- again
Former WA biotechnology company Q-Vis (ASX:QVL) has risen from the ashes to reinvent itself as Salus Technologies. [ + ]
Antisense to establish ADR program
Antisense Therapeutics (ASX: ANP) announced this week it would establish a level 1 American Depository Receipts (ADR) program in the US through the Bank of New York. [ + ]
RNAi experts hope for a knock-out
For Dr John McKinley, CEO of Brisbane RNA-interference therapeutics developer Benitec (ASX:BLT), the power and promise of RNAi technology is captured in one word: druggability. [ + ]
Finding the keys to the world of gene silencing
These are exciting times in medicine: the era of gene-targeting drugs has arrived, promising new standards in safety, selectivity and rational drug design. Antisense oligonucleotides are the best known examples of gene-targeting therapeutic agents. [ + ]
Prima sets sights on $10m capital raising
Melbourne's Prima Biomed (ASX:PRR) is aiming to raise between $5 and $10 million over the next two weeks to fund its research programs - particularly its Panvax vaccine technology. [ + ]
Early results bode well for Psivida's biosilicon
The first four patients with inoperable liver cancer involved in a Phase IIa clinical trial of an in situ radiotherapy treatment developed by Perth nano-biotech company Psivida (ASX:PSD) have experienced regressions of up to 60 per cent in their tumours. [ + ]
